ACTIVE A Trial
Jump to navigation
Jump to search
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
ACTIVE A is a randomized controlled trial of Clopidogrel vs ASA vs Placebo + ASA in the management of atrial fibrillation. 11% were previously on oral anticoagulants, but to enter the trial the patient could not remains on an anticoagulant during the trial.
Inclusion criteria
Documented atrial fibrillation Risk factor for stroke (similar to CHADS score)
Exclusion
Requirement for clopidogrel Risk factors for bleeding
Design
Randomized controlled trial. Clopidogrel vs ASA vs Placebo + ASA
Sample size
N=7,554
Primary Endpoints
Efficacy Endpoint
Endpoints are being adjudicated
Stroke: Clinical definition, adjudicated
Vascular death:
MI:
Systemic embolism: Documented with non invasive study
Safety Endpoint
Major hemorrhage: 2 unit transfusion, death, 5 g/dl drop in Hb.
Planned date of presentation
ACC 2009
Physicians could elect to enroll patients in this trial, or in ACTIVE W.